Dengue is the most prevalent mosquito-borne viral disease causing disease in humans. Dengue disease may present as a non-specific febrile illness, dengue fever (DF), or as a more severe infection marked by hemorrhage or circulatory failure or shock, dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). There are currently no licensed vaccines or therapeutics for dengue virus (DENV). Our laboratory has optimized and utilized human ex vivo models for virus infections, which have been very useful for elucidating mechanisms of innate immune evasion by DENV in specific cell types. Understanding virus-host interactions during DENV infections and the molecular mechanisms involved in the generation of immune responses is one of the crucial factors that will lead to the development of effective and safe vaccines and therapeutics. This project will analyze immune responses to DENV infections ex vivo using two robust systems of human PBMCs and DCs, which are targets for DENV infection in humans. This controlled system of DENV infection captures early events of the virus-host interaction. We will profile innate immune responses to DENV primary isolates circulating in Nicaragua (Project 1) and DENV vaccine strains (Takeda Vaccines Inc., Project 2). Selected strains will be then used for the in depth characterization of the innate immune response, cellular transcriptome, epigenome and proteome in collaboration with the Genomics (Core B), Proteomics (Core C) and immune monitoring Core (Core D) in PBMCs or DCs upon viral exposure. We will identify host proteins that differentially mediate innate immune responses and impact viral replication with the same DENV isolates and vaccines strains by siRNA screens in DCs. Data will be managed and analyzed by the Data Analysis and Modeling Core (Core E) and the Data Management and Dissemination Core (Core F) to define parameters and build cellular and molecular networks important for innate immunity to DENV. Networks will be subsequently integrated with those generated from in vivo studies in Projects 1 (natural infections) and 2 (vaccine trials). Also, our ex vivo systems will serve to identify sets of genes through global analysis to design targeted assays for in vivo studies in Projects 1 and 2 and to validate the role of specific genes important for innate immunity to DENV infection identified in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI118610-03
Application #
9293243
Study Section
Special Emphasis Panel (ZAI1-LGR-I)
Project Start
Project End
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
3
Fiscal Year
2017
Total Cost
$623,086
Indirect Cost
$153,467
Name
Icahn School of Medicine at Mount Sinai
Department
Type
Domestic Higher Education
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Tripathi, Shashank; Garcia-Sastre, Adolfo (2016) Antiviral innate immunity through the lens of systems biology. Virus Res 218:10-7
Coloma, Javier; Jain, Rinku; Rajashankar, Kanagalaghatta R et al. (2016) Structures of NS5 Methyltransferase from Zika Virus. Cell Rep 16:3097-102
Grant, Alesha; Ponia, Sanket S; Tripathi, Shashank et al. (2016) Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling. Cell Host Microbe 19:882-90
Jain, Rinku; Coloma, Javier; García-Sastre, Adolfo et al. (2016) Structure of the NS3 helicase from Zika virus. Nat Struct Mol Biol 23:752-4
Heaton, Nicholas S; Moshkina, Natasha; Fenouil, Romain et al. (2016) Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection. Immunity 44:46-58